To evaluate the effectiveness of T1 and T2 mapping in assessing HER2 and PD-L1 expression in bladder cancer non-invasively.
Utilized T1 and T2 magnetic resonance imaging (MRI) mapping techniques.
Focused on reproducibility of quantitative metrics in bladder cancer assessment.
Assessed HER2 and PD-L1 expression levels through imaging analysis.
Demonstrated reproducibility of T1 and T2 mapping metrics.
Indicated potential for non-invasive assessment of HER2 and PD-L1 expressions in bladder cancer.
Abstract
Preliminary evidence suggests that T1 and T2 mapping can yield reproducible quantitative metrics, which may offer a means to non-invasively assess HER2 and PD-L1 expression in bladder cancer.